Celadon Pharmaceuticals (CEL) Competitors GBX 13.40 0.00 (0.00%) As of 07/22/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesBuy This Stock CEL vs. CNSL, OTT, BCE, FOX, CZN, CHT, DVW, BRCI, NPT, and RCIShould you be buying Celadon Pharmaceuticals stock or one of its competitors? The main competitors of Celadon Pharmaceuticals include Cambridge Nutritional Sciences (CNSL), Oxford Technology 3 Venture Capital Trust (OTT), Beacon Energy (BCE), Fox Marble (FOX), Curzon Energy (CZN), 290005 (CHT.L) (CHT), 5008 (DVW.L) (DVW), BlackRock Comms Income Inv Tst (BRCI), NetPlay TV (NPT), and RapidCloud International (RCI). These companies are all part of the "communication" industry. Celadon Pharmaceuticals vs. Its Competitors Cambridge Nutritional Sciences Oxford Technology 3 Venture Capital Trust Beacon Energy Fox Marble Curzon Energy 290005 (CHT.L) 5008 (DVW.L) BlackRock Comms Income Inv Tst NetPlay TV RapidCloud International Cambridge Nutritional Sciences (LON:CNSL) and Celadon Pharmaceuticals (LON:CEL) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, media sentiment, valuation, profitability and institutional ownership. Does the media favor CNSL or CEL? In the previous week, Cambridge Nutritional Sciences' average media sentiment score of 0.00 equaled Celadon Pharmaceuticals'average media sentiment score. Company Overall Sentiment Cambridge Nutritional Sciences Neutral Celadon Pharmaceuticals Neutral Which has more volatility and risk, CNSL or CEL? Cambridge Nutritional Sciences has a beta of 3.89, suggesting that its share price is 289% more volatile than the S&P 500. Comparatively, Celadon Pharmaceuticals has a beta of -0.26, suggesting that its share price is 126% less volatile than the S&P 500. Is CNSL or CEL more profitable? Cambridge Nutritional Sciences has a net margin of -3.36% compared to Celadon Pharmaceuticals' net margin of -4,024.62%. Cambridge Nutritional Sciences' return on equity of -3.34% beat Celadon Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Cambridge Nutritional Sciences-3.36% -3.34% -2.36% Celadon Pharmaceuticals -4,024.62%-187.26%-34.40% Do institutionals and insiders believe in CNSL or CEL? 10.2% of Cambridge Nutritional Sciences shares are held by institutional investors. Comparatively, 10.7% of Celadon Pharmaceuticals shares are held by institutional investors. 10.9% of Cambridge Nutritional Sciences shares are held by insiders. Comparatively, 65.1% of Celadon Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has better earnings & valuation, CNSL or CEL? Cambridge Nutritional Sciences has higher revenue and earnings than Celadon Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCambridge Nutritional Sciences£9.77M0.86-£3.03MN/AN/ACeladon Pharmaceuticals£123.38K66.61-£4.97M-£7.98-1.68 SummaryCambridge Nutritional Sciences beats Celadon Pharmaceuticals on 6 of the 10 factors compared between the two stocks. Get Celadon Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CEL and its competitors with MarketBeat's FREE daily newsletter. Email Address CEL vs. The Competition Export to ExcelMetricCeladon PharmaceuticalsDrug Manufacturers IndustryMedical SectorLON ExchangeMarket Cap£8.22M£2.19B£5.57B£3.07BDividend YieldN/A2.92%4.05%5.02%P/E Ratio-1.684.2028.09162.65Price / Sales66.61587.54403.61299,584.54Price / Cash3.0510.3536.1927.97Price / Book3.5311.228.604.69Net Income-£4.97M£21.15B£3.24B£5.90B7 Day PerformanceN/A1.75%3.53%7.42%1 Month Performance34.00%7.05%10.99%15.02%1 Year Performance-78.56%2.65%35.25%80.02% Celadon Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CELCeladon PharmaceuticalsN/AGBX 13.40flatN/AN/A£8.22M£123.38K-1.682,780CNSLCambridge Nutritional SciencesN/AGBX 3.63-5.6%N/A-13.1%£8.65M£9.77M-362.103,200Gap UpOTTOxford Technology 3 Venture Capital TrustN/AN/AN/AN/A£2.13M-£85K-12.59203Gap DownBCEBeacon EnergyN/AGBX 0flatN/AN/A£740KN/A-0.3544,600FOXFox MarbleN/AGBX 0.04-7.0%N/A-97.1%£167K£722.06K-135.0010,600Gap DownCZNCurzon EnergyN/AN/AN/AN/A£34KN/A-3.4014,700Gap DownCHT290005 (CHT.L)N/AN/AN/AN/A£0.00N/A0.0020,300DVW5008 (DVW.L)N/AN/AN/AN/A£0.00N/A0.00N/AGap UpBRCIBlackRock Comms Income Inv TstN/AN/AN/AN/A£0.00N/A0.00N/AHigh Trading VolumeNPTNetPlay TVN/AN/AN/AN/A£0.00N/A0.00147,000RCIRapidCloud InternationalN/AN/AN/AN/A£0.00N/A0.0023,000 Related Companies and Tools Related Companies Cambridge Nutritional Sciences Competitors Oxford Technology 3 Venture Capital Trust Competitors Beacon Energy Competitors Fox Marble Competitors Curzon Energy Competitors 290005 (CHT.L) Competitors 5008 (DVW.L) Competitors BlackRock Comms Income Inv Tst Competitors NetPlay TV Competitors RapidCloud International Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (LON:CEL) was last updated on 7/24/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredTrump’s $100 Trillion Land Rush Is OnWhat Is "The US: IPO"? You won't hear this on CNBC... but the government may soon open up hundreds of trill...Stansberry Research | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBREAKING: The House just passed 3 pro-crypto bills!Experts Believe Altcoin Season is Here! With this new legislation in effect, crypto experts across the coun...Crypto 101 Media | SponsoredFREE GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...GoldCo Precious Metals | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Celadon Pharmaceuticals Plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Celadon Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
